Clinical Scorecard: Significant Increases in Blood Pressure Observed During Detrusor Injection of Botulinum Toxin A
At a Glance
Category
Detail
Condition
Overactive bladder (OAB), including idiopathic OAB and neurogenic bladder due to multiple sclerosis (MS)
Key Mechanisms
Onabotulinumtoxin A (OnabotA) detrusor injection reduces urinary urgency and incontinence by targeting bladder muscle activity
Target Population
Adult female patients with idiopathic OAB or neurogenic bladder due to MS who have failed or not tolerated first-line therapies
Care Setting
Outpatient or operating room setting with local anaesthesia for awake patients
Key Highlights
OnabotA detrusor injection significantly reduces urinary incontinence episodes, urgency, frequency, and nocturia in OAB patients.
Procedure is commonly performed under local anaesthesia with patients awake, preferred over sedation or general anaesthesia.
Significant increases in systolic and diastolic blood pressure and rate pressure product (RPP) observed during injection, indicating cardiac stress.
Guideline-Based Recommendations
Diagnosis
Confirm OAB diagnosis by excluding urinary tract infection and other pathologies via urine analysis and bladder ultrasound.
Assess patient history including prior hypertension and response to anticholinergic or β3-sympathomimetic medications.
Management
Use OnabotA detrusor injection after failure or intolerance of conservative first-line therapies.
Perform injections under local anaesthesia with 2% lidocaine intravesical instillation.
Exclude patients with resting systolic BP >190 mmHg or diastolic BP >120 mmHg prior to injection.
Monitoring & Follow-up
Measure blood pressure and heart rate before, during, and 5 minutes after injection to monitor hemodynamic changes.
Identify high-risk patients with elevated resting blood pressure for closer cardiovascular monitoring.
Risks
Potential for significant increases in blood pressure and myocardial workload during injection procedure.
Risk stratification needed for patients with known hypertension or high baseline blood pressure.
Patient & Prescribing Data
Adult females with idiopathic OAB or neurogenic bladder due to MS, average age 64 years
OnabotA injections reduce OAB symptoms and medication use but require cardiovascular monitoring due to transient blood pressure increases during procedure.
Clinical Best Practices
Screen patients for hypertension and exclude those with dangerously high resting blood pressure prior to OnabotA injection.
Prefer local anaesthesia with patients awake to reduce procedural risks and improve tolerability.
Continuously monitor blood pressure and heart rate during injection to detect and manage acute cardiovascular stress.
Provide patient education on potential cardiovascular effects and ensure antihypertensive medications are taken on injection day.
Consider repeat injections carefully, monitoring for amplified cardiovascular stress parameters.
